Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2011

01-07-2011 | Melanomas

Standardizing Regional Therapy: Developing a Consensus on Optimal Utilization of Regional Chemotherapy Treatments in Melanoma

Authors: Georgia M. Beasley, MD, Douglas S. Tyler, MD

Published in: Annals of Surgical Oncology | Issue 7/2011

Login to get access

Excerpt

In this issue of Annals of Surgical Oncology, Huismans et al. describe their extensive experience with isolated limb infusion (ILI) in the treatment of 185 patients with in-transit melanoma over a 15-year period (1992–2007).1 The group initially described and introduced the technique of ILI in the early 1990s as a minimally invasive alternative to hyperthermic isolated limb perfusion (HILP) whereby placement of percutaneously placed catheters allows delivery of regional chemotherapy (usually melphalan plus dactinomycin) to an isolated limb.2 Because of the safety and efficacy of the treatment as well as disappointing results of a multicenter HILP trial, ILI is now utilized at several major U.S. centers and has been demonstrated to be a well-tolerated treatment alternative for patients with advanced extremity melanoma.3‐7 …
Literature
1.
Huisman AM, Kroon HM, Kam PCA, Thomspon JF. Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? Ann Surg Oncol, in press.
2.
Thompson JF, Waugh RC, Saw RPM, Kam PCA. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188–92.
3.
Kroon HM, Moncrieff M, Kam PCA, et al. Outcomes following isolated limb infusion for melanoma: a 14-year experience. Ann Surg Oncol. 2008;15:3003–13.PubMedCrossRef
4.
Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15:2195–205.PubMedCrossRef
5.
Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006;24:4196–201.PubMedCrossRef
6.
Beasley GM, Caudle A, Petersein RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009;208:706–15.PubMedCrossRef
7.
Santillan AA, Delma KA, Beasley GM, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol. 2009;16:2570–8.PubMedCrossRef
8.
Lindner P, Doubrovsky AD, Kam PCA, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. 2002;9:127–36.PubMed
9.
Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg. 1985;15:32–35.CrossRef
10.
Thompson JF, Lai DT, Inguar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res. 1994;S1:45–50.
11.
Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. Presented at the annual meeting of the Southern Surgical Association. December 2010. West Palm Beach, FL.
12.
Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg. 2007;245:591–6.PubMedCrossRef
13.
McMahon N, Beasley GM, Sanders G, et al. A phase I study of systemic sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma (abstract). J Clin Oncol. 2009;27(15 Suppl):9065.
14.
Beasley GM, McMahon N, Sanders G, et al. A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer. 2009;115:4766–74.PubMedCrossRef
15.
Beasley GM, Riboh J, Augustine CK, et al. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol. 2011. doi:10.​1200/​JCO.​2010.​32.​1224.
16.
Ueno T, Ko SH, Grubbs E, et al. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg. 2004;188:532–7.PubMedCrossRef
17.
YoshimotoY, Augustine CK, Yoo J, et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol Cancer Ther. 2007;6:1492–500.PubMedCrossRef
18.
Grubbs EG, Abdel-Wahab O, Cheng TY, et al. In-transit melanoma: the role of alkylating-agent resistance in regional therapy. J Am Coll Surg. 2004;199:419–27.PubMedCrossRef
19.
Abdel-Wahab OI, Grubbs E, Viglianti B, et al. The role of hyperthermia in regional alkylating agent chemotherapy. Clin Cancer Res. 2004;10:5919–29.PubMedCrossRef
20.
Parmiani G, Rivoltini L. Biologic agents as modifiers of chemotherapeutic effects. Curr Opin Oncol. 1991;3:1078–86.
21.
Fraker DL, Alexander HR, Andrich M, et al. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon-gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol. 1996;14:479–89.PubMed
22.
Grunhagen DJ, Brunstein F, Graveland WJ, et al. One hundred consecutive isolated limb perfusions with TNF-alpha and melpahlan in melanoma patients with multiple in-transit metastases. Ann Surg. 2004;240:939–47.PubMedCrossRef
23.
Grubbs EG, Ueno T, Abdel-Wahab O, et al. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery. 2004;136:210–8.PubMedCrossRef
24.
Augustine CK, Yoshimoto Y, Gupta M et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res. 2008;68:3777–84.PubMedCrossRef
25.
Augustine CK, Toshimitsu H, Jung SH, et al. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther. 2010;9:2090–101.PubMedCrossRef
26.
Padussis JC, Augustine CK, Tyler DS. Bevacizumab augmentation or regional melphalan in a melanoma xenograft model. Ann Surg Oncol. 2010;17S:S108.
27.
O’Day SJ, Harnid O, Urba WJ. Targeting cytotoxis T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110:2614–27.PubMedCrossRef
28.
Ueno T, Ko SH, Grubbs E. A novel regional strategy for extremity melanoma using modulation of chemotherapy resistance: intra-arterial temozolomide plus systemic O6-benzylguanine. Mol Cancer Ther. 2006;5:732–8.PubMedCrossRef
29.
Toshimitsu H, Yoshimoto Y. Augustine CK. Inhibition of poly-{ADP-ribose} polymerase activity enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity melanoma. Ann Surg Oncol. 2010;17:2247–54.
Metadata
Title
Standardizing Regional Therapy: Developing a Consensus on Optimal Utilization of Regional Chemotherapy Treatments in Melanoma
Authors
Georgia M. Beasley, MD
Douglas S. Tyler, MD
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1656-9

Other articles of this Issue 7/2011

Annals of Surgical Oncology 7/2011 Go to the issue

Endocrine Tumors

Minimal Extrathyroidal Extension in Patients with Papillary Thyroid Microcarcinoma: Is It a Real Prognostic Factor?

Melanomas

Does Increased Experience with Isolated Limb Infusion for Advanced Limb Melanoma Influence Outcome? A Comparison of Two Treatment Periods at a Single Institution

Gastrointestinal Oncology

Combination of Ex Vivo Sentinel Lymph Node Mapping and Methylene Blue-Assisted Lymph Node Dissection in Gastric Cancer: A Prospective and Randomized Study

Translational Research and Biomarkers

Inhibition of p600 Expression Suppresses Both Invasiveness and Anoikis Resistance of Gastric Cancer

Gastrointestinal Oncology

Comparison of 6th and 7th AJCC TNM Staging Classification for Carcinoma of the Stomach in China

Urologic Oncology

Association Between the Number of Dissected Lymph Nodes During Pelvic Lymphadenectomy and Cancer-Specific Survival in Patients with Lymph Node–Negative Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy